



August 24, 2022

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We are pleased to announce that the Company has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated with the brands), which will enable the Company to provide comprehensive and best-in-class treatment options for diabetes management. Particulars are as under: -

Name of the Acquirer - Lupin Limited

a)	name of the target entity, details in brief such as size, turnover etc.;	Acquisition of brands 'Ondero' and 'Ondero Met' from Boehringer Ingelheim International GmbH.
b)	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at 'arms-length';	No.
c)	industry to which the entity being acquired belongs;	Pharmaceuticals.
d)	objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The brands relate to medicines for the diabetic segment. Value creation is expected for Lupin's diabetic portfolio.
e)	brief details of any governmental or regulatory approvals required for the acquisition;	No government/regulatory approvals are required.
f)	indicative time period for completion of the acquisition;	August 2023.
g)	nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration.
h)	cost of acquisition of brands;	Euro 26 million.



i)	percentage of shareholding / control acquired and / or number of shares acquired; and	N/A.
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Boehringer Ingelheim International GmbH is a company incorporated under the laws of Germany. It is engaged in the pharmaceutical industry.

This may kindly be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS -1 1973)